STOCK TITAN
  1. Home
  2. News
  3. NUVL

Nuvalent Inc - NUVL STOCK NEWS

Welcome to our dedicated news page for Nuvalent (Ticker: NUVL), a resource for investors and traders seeking the latest updates and insights on Nuvalent.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuvalent's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuvalent's position in the market.

News
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
Rhea-AI Summary
Nuvalent, Inc. presents new preclinical data for NVL-330 and zidesamtinib at AACR Annual Meeting. NVL-330 shows broad activity against HER2 oncogenic alterations and higher CNS penetration. Zidesamtinib demonstrates effectiveness against ROS1 resistance mutations and potential for deep, durable responses. Company plans Phase 1 trials for HER2 program and updates on ARROS-1 trial in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
clinical trial
-
News
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
Rhea-AI Summary
Nuvalent, Inc. (NUVL) announced preclinical data poster presentations at AACR Annual Meeting 2024 for its novel HER2-selective inhibitor, NVL-330, and ROS1-selective inhibitor, zidesamtinib (NVL-520). The presentations aim to characterize the compounds' profiles in cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences clinical trial
-
News
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Nuvalent, Inc. highlights pipeline progress, key milestones, and financial results for Q4 and full year 2023. The company's well-capitalized position is expected to support operations until 2027. Nuvalent's recent achievements include FDA breakthrough therapy designation for NVL-520, initiation of Phase 2 trials, and leadership promotions. Financially, the company reported a cash position of $719.9 million, with R&D expenses at $35.6 million in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
earnings
News
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Rhea-AI Summary
Nuvalent, Inc. receives FDA breakthrough therapy designation for NVL-520 in treating ROS1-positive metastatic NSCLC. The drug targets patients with resistance mutations after prior treatments, offering hope for a population with limited options. NVL-520 aims to address challenges like treatment resistance, brain metastases, and CNS adverse events, setting it apart from current therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
News
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
Rhea-AI Summary
Nuvalent, Inc. initiates Phase 2 of ALKOVE-1 trial for NVL-655 with FDA-recommended dose of 150 mg daily. The Phase 1 portion showed promising results in ALK-positive NSCLC patients, with no maximum tolerated dose reached. The Phase 2 design aims to investigate NVL-655 in pre-treated and TKI-naïve patients globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
clinical trial
-
News
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Rhea-AI Summary
Nuvalent, Inc. (NUVL) is set to participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference. The chat will feature the CEO and CFO and will be available via live webcast on the company's website. The event aims to discuss the company's focus on creating targeted therapies for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
conferences
News
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
Rhea-AI Summary
Nuvalent, a clinical-stage biopharmaceutical company (Nasdaq: NUVL), announced its 'OnTarget 2026' operating plan to guide efforts towards having its first potential approved product in 2026. The company is well-capitalized to support its 2026 initiatives with an operating runway anticipated into 2027. Nuvalent aims to bring new, potential best-in-class treatments to patients with cancer and will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th at 7:30 a.m. PT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
News
Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Nuvalent, Inc. (NUVL) CEO to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences
-
News
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Nuvalent, Inc. (Nasdaq: NUVL) reported preliminary Phase 1 clinical data from ALKOVE-1 trial of NVL-655, initiated Phase 2 portion of ARROS-1 trial of NVL-520, and continued advancement of NVL-330 toward clinical development. They appointed industry veteran Perrin Wilson Ph.D. as Senior Vice President of Business Development and Strategy. Net proceeds from $300 million public offering, along with cash, cash equivalents, and marketable securities as of September 30, 2023, expected to extend operating runway into 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
earnings
News
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day
Rhea-AI Summary
Nuvalent, Inc. will participate in a fireside chat during the BMO Virtual BioPharma Spotlight Series: Oncology Day on November 8, 2023. The chat will feature James Porter, CEO, and Alexandra Balcom, CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
conferences
Stock NUVL logo
Nuvalent Inc

Nasdaq:NUVL

NUVL Rankings

#1312 Ranked by Market Cap
#486 Ranked by Stock Gains
N/A Ranked by Dividends

NUVL Stock Data

4.20B
32.77M
3.7%
108.89%
10.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About NUVL

nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.